Evidence map›Paper›PMID 27550420›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2017

Tadashi Watabe, Hayato Ikeda, Shushi Nagamori, Pattama Wiriyasermkul, Yoko Tanaka, Sadahiro Naka, Yasukazu Kanai, Kohei Hagiwara, Masanao Aoki, Eku Shimosegawa and 2 more

Abstract readComparative StudyEvaluation Study
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
4.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 66 citations in OpenAlex.

  1. Trial
  2. Optimization of [EJNMMI radiopharmacy and chemistry · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Recent Development of Boron-Containing Small-Molecule Anticancer Agents.ACS pharmacology & translational science · 2025
    Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Evaluation of a CD13 and Integrin αFrontiers in oncology · 2022
    Article
  17. Effect of Coronavirus Disease 2019 Vaccine-Related Lymphadenopathy on Lung Cancer Treatment.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2022
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Tadashi WatabeDepartment of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan. watabe@tracer.med.osaka-u.ac.jp.
Hayato IkedaDepartment of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Shushi NagamoriDepartment of Bio-system Pharmacology, Osaka University Graduate School of Medicine, Osaka, Japan.
Pattama WiriyasermkulDepartment of Bio-system Pharmacology, Osaka University Graduate School of Medicine, Osaka, Japan.
Yoko TanakaDepartment of Bio-system Pharmacology, Osaka University Graduate School of Medicine, Osaka, Japan.
Sadahiro NakaOsaka University Graduate School of Medicine, Osaka University Hospital, Osaka University, Osaka, Japan.
Yasukazu KanaiPET Molecular Imaging Center, Osaka University Graduate School of Medicine, Osaka, Japan.
Kohei HagiwaraDepartment of Bio-system Pharmacology, Osaka University Graduate School of Medicine, Osaka, Japan.
Masanao AokiDepartment of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Eku ShimosegawaDepartment of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Yoshikatsu KanaiDepartment of Bio-system Pharmacology, Osaka University Graduate School of Medicine, Osaka, Japan.
Jun HatazawaDepartment of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Osaka University · JPOsaka University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe purpose of this study was to evaluate the usefulness of L-4-borono-2-

methodsCellular analyses of FBPA were performed to evaluate the transportablity and K

resultsThe cellular analyses showed that FBPA had a lower affinity to a normal cell-type transporter LAT2 and induced less efflux through LAT2 among FBPA, Met, and BPA, while the efflux through LAT1 induced by FBPA was similar among the three compounds. The K

conclusionThis study shows the utility of

Indexed as

AnimalsBoron CompoundsCell Line, TumorFluorodeoxyglucose F18GliomaLarge Neutral Amino Acid-Transporter 1MaleMetabolic Clearance RateMethionineMolecular ImagingMolecular ProbesMolecular Probe TechniquesPhenylalaninePositron-Emission TomographyRadiopharmaceuticalsRats4-borono-2-fluorophenylalanineBoron Compoundscarbon-11 methionineFluorodeoxyglucose F18Large Neutral Amino Acid-Transporter 1MethionineMolecular ProbesPhenylalanineRadiopharmaceuticalsGliomaInflammationLAT1PETRat model

Identifiers

PMID27550420
OpenAlexW2508747657

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.